Expanding the reach of HER2 in solid tumours: A spotlight on tumour-agnostic approaches

touchCONGRESS for touchONCOLOGY Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice. Overview Data reviews with Prof. Rosti Expert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the themes below Clinical themes Approved and emerging TKIs for CML in the first-line setting Approved and emerging TKIs for CML in the second- and later-line settings Potential impact of emerging data on current and future clinical practice The internationally renowned multiple myeloma expert faculty Prof. Gianantonio Rosti: Meldola, Italy Prof. Susanne Saussele: Mannheim, Germany Dr Carla Boquimpani: Rio de Janeiro, Brazil This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan. This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.  For further information visit our website: TBC

touchCONGRESS for touchHAEMATOLOGY Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice. Overview Data reviews with Prof. Rosti Expert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the themes below Clinical themes Approved and emerging TKIs for CML in the first-line setting Approved and emerging TKIs for CML in the second- and later-line settings Potential impact of emerging data on current and future clinical practice The internationally renowned multiple myeloma expert faculty Prof. Gianantonio Rosti: Meldola, Italy Prof. Susanne Saussele: Mannheim, Germany Dr Carla Boquimpani: Rio de Janeiro, Brazil This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan. This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.  For further information visit our website: TBC

touchPANEL DISCUSSION for touchNEUROLOGY Listen to a panel of leading experts discuss best practice in the management of agitation in Alzheimer’s dementia and the potential of new pharmacological approaches that target aspects of the underlying pathophysiology.  The experts Prof. Jeffrey Cummings, University of Nevada, Las Vegas, NV, USA  Prof. Krista Lanctôt, University of Toronto, ON, Canada  Prof. James Galvin, University of Miami, FL, USA    This touchPODCAST is for HCPs outside of the UK only.  This activity is funded by an independent medical education grant from Lundbeck. This activity is jointly provided by USF Health and touchIME in collaboration with the Gerontological Society of America (GSA). For further information visit: https://touchneurologyime.org/cme/curriculums/agitation-in-alzheimers-dementia/   

touchIN CONVERSATION for touchCARDIO Listen to Prof. Manreet Kanwar in conversation with Prof. Jean-Luc Vachiéry, two experts in pulmonary arterial hypertension who are practicing in the USA and Belgium, respectively. They respond to questions submitted by the HCP audience and provide expert insights into the diagnosis of pulmonary arterial hypertension, patient risk stratification to support treatment decision-making and considerations for optimizing patient care in an evolving treatment landscape.  This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. The experts Prof. Manreet Kanwar, Allegheny General Hospital, Pittsburgh, PA, USA Prof. Jean-Luc Vachiéry, Hôpital Universitaire de Bruxelles Erasme, Brussels, Belgium  For further information visit our website:  www.touchCARDIO.com 

touchIN CONVERSATION for touchRESPIRATORY Listen to Prof. Manreet Kanwar in conversation with Prof. Jean-Luc Vachiéry, two experts in pulmonary arterial hypertension who are practicing in the USA and Belgium, respectively. They respond to questions submitted by the HCP audience and provide expert insights into the diagnosis of pulmonary arterial hypertension, patient risk stratification to support treatment decision-making and considerations for optimizing patient care in an evolving treatment landscape.  This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. The experts Prof. Manreet Kanwar, Allegheny General Hospital, Pittsburgh, PA, USA Prof. Jean-Luc Vachiéry, Hôpital Universitaire de Bruxelles Erasme, Brussels, Belgium  For further information visit our website:  www.touchRESPIRATORY.com 

touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  www.touchONCOLOGY.com 

touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  www.touchONCOLOGY.com 

touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  www.touchRESPIRATORY.com 

touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  www.touchRESPIRATORY.com 

touchFOCUS for touchONCOLOGY Listen to Dr Jennifer Carlisle, an expert in lung cancer, as she answers a series of questions on the targeted perioperative treatment strategies and best practices for patients with resectable and unresectable early-stage EGFR-mutant NSCLC. She also discusses how the evolving treatment landscape impacts biomarker testing and the importance of multidisciplinary care for optimizing outcomes in these patients. The expert Dr Jennifer Carlisle, Winship Cancer Institute of Emory University, Atlanta, GA, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchoncology.org/EGFR-mutant-treatment-options-early-NSCLC